Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial-MedSci.cn

Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial

Janjigian, Y; Rha, S; Oh, D; Garcia, MD; van Laarhoven, H; Chao, Y; Di Bartolomeo, M; Mohammad, NH; Zhong, W; Croydon, E; Cecchi, F; Lee, J

ANNALS OF ONCOLOGY, 2022; 33 (): S358

科室
- - 订阅+
  - 更多科室
工具
服务